Fondaparinux and bleeding risk in COVID-19: unsolved question

Thromb Res. 2021 Apr:200:128-129. doi: 10.1016/j.thromres.2021.01.025. Epub 2021 Feb 9.

Authors

Vincenzo Russo¹, Riccardo Proietti², Corrado Lodigiani³, Pierpaolo Di Micco⁴

Affiliations

¹ Cardiology Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli" - Monaldi Hospital, Naples, Italy.
² Cardiology Unit, Sacco Hospital, Milan, Italy.
³ Thrombosis and Hemorragic Center, Humanitas Research Hospital and University, Rozzano, Italy.
⁴ Medicine Unit, Fatebenefratelli Hospital, Naples, Italy. Electronic address: pdimicco@libero.it.

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants / adverse effects
COVID-19*
Enoxaparin*
Fondaparinux
Humans
Retrospective Studies
SARS-CoV-2

Substances

Anticoagulants
Enoxaparin
Fondaparinux